Search

Author/Creator Symmans, F.

1. NEOTALA: an open-label, single-arm, multi-center, phase 2 study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple negative breast cancer (TNBC). (March 2019)

Authors:
Litton, J.; Symmans, F.; Gogineni, K.; Saltzman, M.; Telli, M.L.; Usha, L.; Chakrabarti, J.; Tudor, I.C.; Quek, R.G.W.; Czibere, A.
Journal:
Breast
Issue:
Volume 44(2019)Supplement 1
Page Start:
S73
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning. (October 2018)

Authors:
Klauschen, F.; Müller, K.-R.; Binder, A.; Bockmayr, M.; Hägele, M.; Seegerer, P.; Wienert, S.; Pruneri, G.; de Maria, S.; Badve, S.; Michiels, S.; Nielsen, T.O.; Adams, S.; Savas, P.; Symmans, F.; Willis, S.; Gruosso, T.; Park, M.; Haibe-Kains, B.; Gallas, B.
Journal:
Seminars in cancer biology
Issue:
Volume 52(2018)Part 2
Page Start:
151
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search